2-Bromo-4-methoxy-5-(trifluoromethyl)pyridine | 1227579-45-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Bromo-4-methoxy-5-(trifluoromethyl)pyridine
• 英文别名: 2-bromo-4-methoxy-5-(trifluoromethyl)pyridine
• CAS: 1227579-45-4
• 化学式: C₇H₅BrF₃NO
• 分子量: 256.02
• InChiKey: IRNAIICCZZKNRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10780092B2

  公开（公告）日：2020-09-22

  The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.

  本发明提供了某些式（I）的融合吡嗪化合物或其药学上可接受的盐类，其中 X、Y、R1、R3、R4a、R5a、R5b、R6 和下标 t 如本文所述。本发明的化合物或其药学上可接受的盐类可以调节体内环磷酸鸟苷（"cGMP"）的产生，通常适用于治疗和预防与 cGMP 平衡紊乱有关的疾病或失调。本发明还提供了包含式（I）化合物或其药学上可接受的盐的药物组合物。本发明还涉及将这些化合物或其药学上可接受的盐用于治疗和预防上述疾病和紊乱的方法，以及为此目的制备药物的方法。
• FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3458066A1

  公开（公告）日：2019-03-27
• [EN] FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS<br/>[FR] DÉRIVÉS DE PYRAZINE FUSIONNÉS UTILES EN TANT QUE STIMULATEURS DE GUANYLATE CYCLASE SOLUBLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2017200825A1

  公开（公告）日：2017-11-23

  The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ("cGMP"), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.